Razavi International Journal of Medicine

Published by: Kowsar

The Relation Between Fecal Calprotectin and the Rate of Clinical Activity of Ulcerative Colitis

Hassan Vosoughinia 1 , 2 , Maryam Latifnia 3 , Mojtaba Fattahi Abdizadeh 4 , Elham Mokhtari Amirmajdi 2 , 5 and Mitra Ahadi 2 , 6 , *
Authors Information
1 Associate Professor, Gastroenterology and Hepatology, Mashhad University of Medical Sciences, Mashhad, Iran
2 Gastroenterology and Hepatology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
3 Assistant Professor, Gastroenterology and Hepatology, Sabzevar University of Medical Sciences, Sabzevar, Iran
4 Assistant Professor of Microbiology, Sabzevar University of Medical Sciences, Sabzevar, Iran
5 Assistant Professor, Gastroenterology, Department of Internal Medicine, Mashhad Branch, Islamic Azad University, Mashhad, Iran
6 Assistant Professor, Gastroenterology and Hepatology, Mashhad University of Medical Sciences, Mashhad, Iran
Article information
  • Razavi International Journal of Medicine: March 2018, 6 (1); e14533
  • Published Online: January 13, 2018
  • Article Type: Research Article
  • Received: June 7, 2017
  • Revised: July 12, 2017
  • Accepted: November 8, 2017
  • DOI: 10.5812/rijm.14533

To Cite: Vosoughinia H, Latifnia M, Fattahi Abdizadeh M, Mokhtari Amirmajdi E, Ahadi M. The Relation Between Fecal Calprotectin and the Rate of Clinical Activity of Ulcerative Colitis, Razavi Int J Med. 2018 ; 6(1):e14533. doi: 10.5812/rijm.14533.

Copyright © 2018, Razavi International Journal of Medicine. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Methods
3. Results
4. Discussion
  • 1. Moris G. Inflammatory bowel disease: an increased risk factor for neurologic complications. World J Gastroenterol. 2014;20(5):1228-37. doi: 10.3748/wjg.v20.i5.1228. [PubMed: 24574797].
  • 2. Ordas I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet. 2012;380(9853):1606-19. doi: 10.1016/S0140-6736(12)60150-0. [PubMed: 22914296].
  • 3. Mosli MH, Feagan BG, Sandborn WJ, D'Haens G, Behling C, Kaplan K, et al. Histologic evaluation of ulcerative colitis: a systematic review of disease activity indices. Inflamm Bowel Dis. 2014;20(3):564-75. doi: 10.1097/01.MIB.0000437986.00190.71. [PubMed: 24412993].
  • 4. Menees SB, Powell C, Kurlander J, Goel A, Chey WD. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol. 2015;110(3):444-54. doi: 10.1038/ajg.2015.6. [PubMed: 25732419].
  • 5. Marie I, Leroi AM, Menard JF, Levesque H, Quillard M, Ducrotte P. Fecal calprotectin in systemic sclerosis and review of the literature. Autoimmun Rev. 2015;14(6):547-54. doi: 10.1016/j.autrev.2015.01.018. [PubMed: 25661980].
  • 6. Burri E, Beglinger C. The use of fecal calprotectin as a biomarker in gastrointestinal disease. Expert Rev Gastroenterol Hepatol. 2014;8(2):197-210. doi: 10.1586/17474124.2014.869476. [PubMed: 24345070].
  • 7. Mark F, Lawrence SF, Lawrence JB. Sleisenger and Fordtran`s Gastrointestinal and liver disease. Pathophysiology/diagnosis/management. 2. 10th ed. United States of America: Elsevier Saunders; 2016. 2040 p.
  • 8. Mao R, Xiao YL, Gao X, Chen BL, He Y, Yang L, et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies. Inflamm Bowel Dis. 2012;18(10):1894-9. doi: 10.1002/ibd.22861. [PubMed: 22238138].
  • 9. Bennike TB, Carlsen TG, Ellingsen T, Bonderup OK, Glerup H, Bogsted M, et al. Neutrophil Extracellular Traps in Ulcerative Colitis: A Proteome Analysis of Intestinal Biopsies. Inflamm Bowel Dis. 2015;21(9):2052-67. doi: 10.1097/MIB.0000000000000460. [PubMed: 25993694].
  • 10. Calafat M, Cabre E, Manosa M, Lobaton T, Marin L, Domenech E. High within-day variability of fecal calprotectin levels in patients with active ulcerative colitis: what is the best timing for stool sampling? Inflamm Bowel Dis. 2015;21(5):1072-6. doi: 10.1097/MIB.0000000000000349. [PubMed: 25793326].
  • 11. Ferreiro-Iglesias R, Barreiro-de Acosta M, Otero Santiago M, Lorenzo Gonzalez A, Alonso de la Pena C, Benitez Estevez AJ, et al. Fecal Calprotectin as Predictor of Relapse in Patients With Inflammatory Bowel Disease Under Maintenance Infliximab Therapy. J Clin Gastroenterol. 2016;50(2):147-51. doi: 10.1097/MCG.0000000000000312. [PubMed: 25811118].
  • 12. Andrisani G, Guidi L, Papa A, Armuzzi A. Anti-TNF alpha therapy in the management of extraintestinal manifestation of inflammatory bowel disease. Eur Rev Med Pharmacol Sci. 2012;16(7):890-901. [PubMed: 22953637].
  • 13. Li Z, Long Y, Bai M, Li J, Feng Z. Neutrophil and Eosinophil Granule Proteins as Potential Biomarkers of Assessing Disease Activity and Severity in Patients With Ulcerative Colitis. J Clin Lab Anal. 2016;30(5):776-8. doi: 10.1002/jcla.21937. [PubMed: 27076259].
  • 14. Sandborn WJ, Panes J, Zhang H, Yu D, Niezychowski W, Su C. Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial. Gastroenterology. 2016;150(1):96-102. doi: 10.1053/j.gastro.2015.09.001. [PubMed: 26376350].
  • 15. Schoepfer AM, Beglinger C, Straumann A, Trummler M, Renzulli P, Seibold F. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis. 2009;15(12):1851-8. doi: 10.1002/ibd.20986. [PubMed: 19462421].
  • 16. Kristensen V, Klepp P, Cvancarova M, Roseth A, Skar V, Moum B. Prediction of endoscopic disease activity in ulcerative colitis by two different assays for fecal calprotectin. J Crohns Colitis. 2015;9(2):164-9. doi: 10.1093/ecco-jcc/jju015. [PubMed: 25518057].
  • 17. Kotze LM, Nisihara RM, Marion SB, Cavassani MF, Kotze PG. FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms. Arq Gastroenterol. 2015;52(1):50-4. doi: 10.1590/S0004-28032015000100011. [PubMed: 26017083].
  • 18. Xiang JY, Ouyang Q, Li GD, Xiao NP. Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis. World J Gastroenterol. 2008;14(1):53-7. [PubMed: 18176961].
  • 19. Lobaton T, Rodriguez-Moranta F, Lopez A, Sanchez E, Rodriguez-Alonso L, Guardiola J. A new rapid quantitative test for fecal calprotectin predicts endoscopic activity in ulcerative colitis. Inflamm Bowel Dis. 2013;19(5):1034-42. doi: 10.1097/MIB.0b013e3182802b6e. [PubMed: 23470502].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments